News

Results from the study demonstrated that the trial did not meet its primary endpoint of non-inferiority in overall treatment response in isavuconazole-treated patients at the end of IV

This recall has been initiated as a precautionary measure due to the identification of a Clopidogrel tablet found in a bottle of the product. The risk associated with

Allergan’s ANDA product is a generic version of United Therapeutics Corporation’s Tyvaso, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. United

This research, conducted at University of California, San Diego, and University of California, Davis, supports the use of dual NOX1&4 inhibitors for the treatment of liver fibrosis, such

AL-704 is a nucleotide based NS5B polymerase inhibitor also known as JNJ-54257099, by Alios Biopharma, part of the Janssen Pharmaceutical Companies. It is intended for the treatment of

The IND acceptance allows the company to start an open-label Phase I trial designed to evaluate the safety, pharmacokinetics and clinical activity of KB003 in previously treated CMML

FX006 is a new, non-opioid, sustained-release, intra-articular (IA) (within the joint) formulation of triamcinolone acetonide (TCA) designed to treat patients with moderate to severe osteoarthritis (OA) pain of

Mogamulizumab is a new, humanized mAb directed against CC chemokine receptor type 4 (CCR4). Opdivo is a PD-1 immune checkpoint inhibitor that has received approval from the US

The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared